Advertisement

Histochemistry and Cell Biology

, Volume 149, Issue 6, pp 635–644 | Cite as

Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer

  • Chien-Liang Liu
  • Po-Sheng Yang
  • Ming-Nan Chien
  • Yuan-Ching Chang
  • Chi-Hsin Lin
  • Shih-Ping Cheng
Original Paper

Abstract

SPINT1, also known as HAI-1, is a Kunitz-type serine protease inhibitor that inhibits multiple proteases including hepatocyte growth factor (HGF) activator and matriptase. SPINT1 has been shown to modulate HGF/MET activation in certain cancer types. In the present study, we analyzed microarray datasets and found that SPINT1 was consistently upregulated in differentiated thyroid cancer. SPINT1 protein expression was investigated using tissue microarrays and independent samples of our 143 patients. Strong SPINT1 expression was observed in 61–68% of papillary thyroid cancer and 41–50% of follicular thyroid cancer. The overexpression diminished in anaplastic thyroid cancer. The SPINT1 expression in normal thyroid tissues and benign thyroid lesions was low. Furthermore, we noted that the SPINT1 expression was associated with extrathyroidal invasion, lymphovascular invasion, lymph node metastasis, advanced TNM stage, and a higher risk of recurrence in differentiated thyroid cancer. The results were in accordance with our analysis of The Cancer Genome Atlas data. In conclusion, an overexpression of SPINT1 appears to be associated with an invasive phenotype in differentiated thyroid cancer.

Keywords

Serine protease inhibitor Hepatocyte growth factor Thyroid cancer Invasion 

Notes

Acknowledgements

This work was supported by research grants from the Ministry of Science and Technology of Taiwan (MOST-104-2314-B-195-004-MY3) and MacKay Memorial Hospital (MMH-10712 and MMH-E-107-10).

Compliance with ethical standards

Informed consent

Institutional review board approval was obtained for the study, and the need for informed consent was waived.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

418_2018_1660_MOESM1_ESM.tif (9.3 mb)
Supplementary material 1 Supplemental Figure 1. (a) Representative image of a tissue microarray slide containing cores from malignant thyroid tumors and corresponding normal thyroid tissues. Red boxes indicate sets of three cores from the same primary tumor. (b) Representative microphotographs from two cases, demonstrating similar expression levels of SPINT1 in different regions of the same tumor. Scale bar, 500 μm (TIF 9536 KB)
418_2018_1660_MOESM2_ESM.tif (230 kb)
Supplementary material 2 Supplemental Figure 2. Scatter plots of H-score of SPINT1 immunohistochemical staining versus clinicopathological factors in differentiated thyroid cancer (n = 143). ATA, American Thyroid Association. MACIS, metastases, age, completeness of resection, invasion, and size (papillary thyroid cancer only). ***, P < 0.001 (TIF 229 KB)

References

  1. Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676–690CrossRefGoogle Scholar
  2. Chang YC, Chen CK, Chen MJ, Lin JC, Lin CH, Huang WC, Cheng SP, Chen SN, Liu CL (2017) Expression of 3β-hydroxysteroid dehydrogenase type 1 in breast cancer is associated with poor prognosis independent of estrogen receptor status. Ann Surg Oncol 24:4033–4041CrossRefPubMedGoogle Scholar
  3. Chen CD, Wang CL, Yu CJ, Chien KY, Chen YT, Chen MC, Chang YS, Wu CC, Yu JS (2014) Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion. J Proteome Res 13:2818–2829CrossRefPubMedGoogle Scholar
  4. Chen CL, Chiang CY, Liao KW, Ho SY, Chang YF, Lim KH, Hsieh RK, Lin YL, Su YW (2017) cIAP-2 expression increases in elderly patients with squamous cell carcinoma of the head and neck. Int J Gerontol 11:22–26CrossRefGoogle Scholar
  5. Cheng SP, Liu CL, Chen MJ, Chien MN, Leung CH, Lin CH, Hsu YC, Lee JJ (2015) CD74 expression and its therapeutic potential in thyroid carcinoma. Endocr Relat Cancer 22:179–190CrossRefPubMedGoogle Scholar
  6. Cheng SP, Yang PS, Chien MN, Chen MJ, Lee JJ, Liu CL (2016) Aberrant expression of tumor-associated carbohydrate antigen Globo H in thyroid carcinoma. J Surg Oncol 114:853–858CrossRefPubMedGoogle Scholar
  7. Cheng SP, Chen MJ, Chien MN, Lin CH, Lee JJ, Liu CL (2017) Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma. Clin Exp Med 17:555–564CrossRefPubMedGoogle Scholar
  8. Chien MN, Yang PS, Lee JJ, Wang TY, Hsu YC, Cheng SP (2017) Recurrence-associated genes in papillary thyroid cancer: an analysis of data from The Cancer Genome Atlas. Surgery 161:1642–1650CrossRefPubMedGoogle Scholar
  9. Funagayama M, Kondo K, Chijiiwa K, Kataoka H (2010) Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes. World J Surg 34:1563–1571CrossRefPubMedGoogle Scholar
  10. Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ (2006) Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8–PPARG translocation. Clin Cancer Res 12:1983–1993CrossRefPubMedGoogle Scholar
  11. Godiksen S, Selzer-Plon J, Pedersen ED, Abell K, Rasmussen HB, Szabo R, Bugge TH, Vogel LK (2008) Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary. Biochem J 413:251–259CrossRefPubMedPubMedCentralGoogle Scholar
  12. Guan H, Liang W, Liu J, Wei G, Li H, Xiu L, Xiao H, Li Y (2015) Transmembrane protease serine 4 promotes thyroid cancer proliferation via CREB phosphorylation. Thyroid 25:85–94CrossRefPubMedPubMedCentralGoogle Scholar
  13. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133CrossRefPubMedPubMedCentralGoogle Scholar
  14. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057PubMedGoogle Scholar
  15. Hebrant A, Dom G, Dewaele M, Andry G, Tresallet C, Leteurtre E, Dumont JE, Maenhaut C (2012) mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One 7:e37807CrossRefPubMedPubMedCentralGoogle Scholar
  16. Hoshiko S, Kawaguchi M, Fukushima T, Haruyama Y, Yorita K, Tanaka H, Seiki M, Inatsu H, Kitamura K, Kataoka H (2013) Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis. Cancer Res 73:2659–2670CrossRefPubMedGoogle Scholar
  17. Ito Y, Akinaga A, Yamanaka K, Nakagawa T, Kondo A, Dickson RB, Lin CY, Miyauchi A, Taniguchi N, Miyoshi E (2006) Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues—its possible role in prolonged stability in vivo by aberrant glycosylation. Glycobiology 16:368–374CrossRefPubMedGoogle Scholar
  18. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL (2003) Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63:1101–1105PubMedGoogle Scholar
  19. Kataoka H, Kawaguchi M (2010) Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo. FEBS J 277:2230–2237CrossRefPubMedGoogle Scholar
  20. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M (2000) Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 60:6148–6159PubMedGoogle Scholar
  21. Kawaguchi M, Kataoka H (2014) Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancers (Basel) 6:1890–1904CrossRefGoogle Scholar
  22. Komaki W, Fukushima T, Tanaka H, Itoh H, Chosa E, Kataoka H (2008) Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses. Virchows Arch 453:347–357CrossRefPubMedGoogle Scholar
  23. Koo BS, Kim JM, Seo ST, Yoon YH, Kwon KR, Kim SH, Kwon HW, Bae WJ, Lim YC (2014) Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol 21:2310–2317CrossRefPubMedGoogle Scholar
  24. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, Negri E (2015) Thyroid cancer mortality and incidence: a global overview. Int J Cancer 136:2187–2195CrossRefPubMedGoogle Scholar
  25. Larrinaga G, Blanco L, Errarte P, Beitia M, Sanz B, Perez I, Irazusta A, Sanchez CE, Santaolalla F, Andres L, Lopez JI (2013) Altered peptidase activities in thyroid neoplasia and hyperplasia. Dis Mark 35:825–832CrossRefGoogle Scholar
  26. Lee JJ, Wang TY, Liu CL, Chien MN, Chen MJ, Hsu YC, Leung CH, Cheng SP (2017) Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma. J Clin Endocrinol Metab 102:2930–2940CrossRefPubMedGoogle Scholar
  27. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM (2017) Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317:1338–1348CrossRefPubMedGoogle Scholar
  28. Maeta H, Ohgi S, Terada T (2001) Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 438:121–128CrossRefPubMedGoogle Scholar
  29. Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP (2017) Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci 108:296–307CrossRefPubMedPubMedCentralGoogle Scholar
  30. Nagaike K, Kohama K, Uchiyama S, Tanaka H, Chijiiwa K, Itoh H, Kataoka H (2004) Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Sci 95:728–735CrossRefPubMedGoogle Scholar
  31. Nagakawa O, Yamagishi T, Akashi T, Nagaike K, Fuse H (2006) Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate 66:447–452CrossRefPubMedGoogle Scholar
  32. Nagata K, Hirono S, Ido A, Kataoka H, Moriuchi A, Shimomura T, Hori T, Hayashi K, Koono M, Kitamura N, Tsubouchi H (2001) Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 289:205–211CrossRefPubMedGoogle Scholar
  33. Nakamura K, Hongo A, Kodama J, Hiramatsu Y (2011) The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int J Cancer 128:2613–2624CrossRefPubMedGoogle Scholar
  34. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC (2002) Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 8:1101–1107PubMedGoogle Scholar
  35. Oberst MD, Chen LY, Kiyomiya K, Williams CA, Lee MS, Johnson MD, Dickson RB, Lin CY (2005) HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol 289:C462–C470CrossRefPubMedGoogle Scholar
  36. Parr C, Jiang WG (2001) Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 19:857–863PubMedGoogle Scholar
  37. Pita JM, Banito A, Cavaco BM, Leite V (2009) Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer 101:1782–1791CrossRefPubMedPubMedCentralGoogle Scholar
  38. Puente XS, Sanchez LM, Gutierrez-Fernandez A, Velasco G, Lopez-Otin C (2005) A genomic view of the complexity of mammalian proteolytic systems. Biochem Soc Trans 33:331–334CrossRefPubMedGoogle Scholar
  39. Ruco LP, Stoppacciaro A, Ballarini F, Prat M, Scarpino S (2001) Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. J Pathol 194:4–8CrossRefPubMedGoogle Scholar
  40. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H (2006) A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomark Prev 15:217–227CrossRefGoogle Scholar
  41. Scarpino S, Cancellario d’Alena F, Di Napoli A, Pasquini A, Marzullo A, Ruco LP (2004) Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352–358CrossRefPubMedGoogle Scholar
  42. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N (1997) Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 272:6370–6376CrossRefPubMedGoogle Scholar
  43. Shimwell NJ, Bryan RT, Wei W, James ND, Cheng KK, Zeegers MP, Johnson PJ, Martin A, Ward DG (2013) Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. Br J Cancer 108:1854–1861CrossRefPubMedPubMedCentralGoogle Scholar
  44. Tanabe LM, List K (2017) The role of type II transmembrane serine protease-mediated signaling in cancer. FEBS J 284:1421–1436CrossRefPubMedGoogle Scholar
  45. Ulisse S, Baldini E, Sorrenti S, Barollo S, Gnessi L, Catania A, Pellizzo MR, Nardi F, Mian C, De Antoni E, D’Armiento M, Frati L (2011) High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab 96:504–508CrossRefPubMedGoogle Scholar
  46. Wang TY, Liu CL, Chen MJ, Lee JJ, Pun PC, Cheng SP (2015) Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer. Histopathology 66:447–456CrossRefPubMedGoogle Scholar
  47. Wang CW, Lee YC, Calista E, Zhou F, Zhu H, Suzuki R, Komura D, Ishikawa S, Cheng SP (2018) A benchmark for comparing precision medicine methods in thyroid cancer diagnosis using tissue microarrays. Bioinformatics.  https://doi.org/10.1093/bioinformatics/btx838 CrossRefPubMedPubMedCentralGoogle Scholar
  48. Yen TY, Bowen S, Yen R, Piryatinska A, Macher BA, Timpe LC (2017) Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile. J Proteome Res 16:1391–1400CrossRefPubMedPubMedCentralGoogle Scholar
  49. Zheng Q, Wu H, Cao J, Ye J (2014) Hepatocyte growth factor activator inhibitor type-1 in cancer: advances and perspectives (Review). Mol Med Rep 10:2779–2785CrossRefPubMedGoogle Scholar
  50. Zurawa-Janicka D, Kobiela J, Galczynska N, Stefaniak T, Lipinska B, Lachinski A, Skorko-Glonek J, Narkiewicz J, Proczko-Markuszewska M, Sledzinski Z (2012) Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors. Oncol Rep 28:1838–1844CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryMacKay Memorial Hospital and Mackay Medical CollegeTaipeiTaiwan
  2. 2.Department of Medical ResearchMacKay Memorial HospitalTaipeiTaiwan
  3. 3.Division of Endocrinology and Metabolism, Department of Internal MedicineMacKay Memorial Hospital and Mackay Medical CollegeTaipeiTaiwan
  4. 4.Department of Bioscience TechnologyChung Yuan Christian UniversityTaoyuanTaiwan
  5. 5.Department of Pharmacology, Graduate Institute of Medical SciencesTaipei Medical UniversityTaipeiTaiwan

Personalised recommendations